| Mr Robert Holland, CRNA | |
|
910 Wallace Ave, Leitchfield, KY 42754 | |
| (270) 274-0480 | |
| (270) 274-0482 |
| Full Name | Mr Robert Holland |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 13 Years |
| Location | 910 Wallace Ave, Leitchfield, Kentucky |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427434026 | NPI | - | NPPES |
| 7100378870 | Medicaid | KY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 3009649 (Kentucky) | Primary |
| 367500000X | Nurse Anesthetist, Certified Registered | 106744 (Kentucky) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hazard Arh Regional Medical Center | Hazard, KY | Hospital |
| Whitesburg Arh Hospital | Whitesburg, KY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Triangle Anesthesia Group, Psc | 9436161585 | 68 |
News Archive
A new year often means a list of resolutions for change, such as abstaining from drinking alcohol, stopping smoking, or living a healthier lifestyle. For one, "Dry January" has become immensely popular because it motivates people to abstain from drinking alcohol for 30 days, at least.
In an effort to combine sophisticated laser and Internet technologies, scientists in Australia have successfully performed laser surgery and "optical trapping" in a Southern California laboratory via the Internet.
A team of scientists from the University of Valencia and INCLIVA Health Research Institute, Spain, has recently investigated the durability of immune responses specifically developed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19).
Human Genome Sciences, Inc. today announced interim results through Week 12 following the end of treatment in a Phase 2b clinical trial conducted by Novartis to evaluate the safety and efficacy of ZALBIN™ (albinterferon alfa-2b), an investigational agent, administered monthly in combination with ribavirin in 391 treatment-naive patients with genotypes 2 and 3 chronic hepatitis C virus. The primary efficacy endpoint is sustained virologic response (SVR) at Week 48 (24 weeks following the end of treatment).
Genetic variation due to DNA mutation is a driving force of adaptation and evolution, as well as a contributing factor to disease. However, the mechanisms governing DNA mutation rate are not well understood.
› Verified 1 days ago
| Entity Name | Triangle Anesthesia Group, Psc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124079314 PECOS PAC ID: 9436161585 Enrollment ID: O20060608000180 |
News Archive
A new year often means a list of resolutions for change, such as abstaining from drinking alcohol, stopping smoking, or living a healthier lifestyle. For one, "Dry January" has become immensely popular because it motivates people to abstain from drinking alcohol for 30 days, at least.
In an effort to combine sophisticated laser and Internet technologies, scientists in Australia have successfully performed laser surgery and "optical trapping" in a Southern California laboratory via the Internet.
A team of scientists from the University of Valencia and INCLIVA Health Research Institute, Spain, has recently investigated the durability of immune responses specifically developed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19).
Human Genome Sciences, Inc. today announced interim results through Week 12 following the end of treatment in a Phase 2b clinical trial conducted by Novartis to evaluate the safety and efficacy of ZALBIN™ (albinterferon alfa-2b), an investigational agent, administered monthly in combination with ribavirin in 391 treatment-naive patients with genotypes 2 and 3 chronic hepatitis C virus. The primary efficacy endpoint is sustained virologic response (SVR) at Week 48 (24 weeks following the end of treatment).
Genetic variation due to DNA mutation is a driving force of adaptation and evolution, as well as a contributing factor to disease. However, the mechanisms governing DNA mutation rate are not well understood.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Robert Holland, CRNA 1100 Riverwood Rd, Murray, KY 42071-9393 Ph: (270) 705-7368 | Mr Robert Holland, CRNA 910 Wallace Ave, Leitchfield, KY 42754 Ph: (270) 274-0480 |
News Archive
A new year often means a list of resolutions for change, such as abstaining from drinking alcohol, stopping smoking, or living a healthier lifestyle. For one, "Dry January" has become immensely popular because it motivates people to abstain from drinking alcohol for 30 days, at least.
In an effort to combine sophisticated laser and Internet technologies, scientists in Australia have successfully performed laser surgery and "optical trapping" in a Southern California laboratory via the Internet.
A team of scientists from the University of Valencia and INCLIVA Health Research Institute, Spain, has recently investigated the durability of immune responses specifically developed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19).
Human Genome Sciences, Inc. today announced interim results through Week 12 following the end of treatment in a Phase 2b clinical trial conducted by Novartis to evaluate the safety and efficacy of ZALBIN™ (albinterferon alfa-2b), an investigational agent, administered monthly in combination with ribavirin in 391 treatment-naive patients with genotypes 2 and 3 chronic hepatitis C virus. The primary efficacy endpoint is sustained virologic response (SVR) at Week 48 (24 weeks following the end of treatment).
Genetic variation due to DNA mutation is a driving force of adaptation and evolution, as well as a contributing factor to disease. However, the mechanisms governing DNA mutation rate are not well understood.
› Verified 1 days ago
John Anthony Lyons, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 904 Wallace Ave, Leitchfield, KY 42754 Phone: 270-259-9470 | |
Rodney D Mann, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 910 Wallace Ave, Leitchfield, KY 42754 Phone: 270-259-9512 | |
Jared Crocker, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 910 Wallace Ave, Leitchfield, KY 42754 Phone: 270-274-0480 | |
Mrs. Merry Lynn Green, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 904 Wallace Ave, Leitchfield, KY 42754 Phone: 270-259-9470 Fax: 270-259-1662 | |
Callie J Hancock, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 910 Wallace Ave, Leitchfield, KY 42754 Phone: 270-259-9512 | |
Mrs. Richelle Lynn Humphrey, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 904 Wallace Ave, Leitchfield, KY 42754 Phone: 270-259-9470 | |
Susan Kirkwood, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 317 N English St, Leitchfield, KY 42754 Phone: 502-550-4164 |